Loading
When a blood test says 'cancer signal, origin unclear', a FAPI PET scan may find it where FDG cannot.
When a blood test reports a cancer signal of unclear origin, this idea sends the patient for FAPI PET/CT rather than FDG PET as the first-line work-up. Many MCED-positive patients have no cancer found on standard imaging, which creates anxiety and cost, whereas FAPI PET is more sensitive than FDG in pancreatic, gastric, low-grade and peritoneal disease, exactly the cancers MCED promises to catch, and has low background in liver, brain and bowel. The test is a prospective diagnostic study nested in a Galleri deployment such as the NHS or a PATHFINDER-like cohort, randomising FDG versus FAPI PET. Speculative in maturity, it addresses the bottleneck The hardest cancers are found late and is linked from the ideas on a 28-day MCED-positive resolution pathway and whole-population interception.
Shares Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares FAPI PET, FAP, Pancreatic ductal adenocarcinoma.
Shares Multi-cancer early detection (MCED), Ovarian cancer, Pancreatic ductal adenocarcinoma.
Shares Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares FAPI PET, FAP, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
Shares Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late, Pancreatic ductal adenocarcinoma.
Shares A 28-day national pathway for people with a positive multi-cancer blood test, Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares FAPI PET, FAP, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.